Study of the Spread of COVID-19 in Saint Petersburg, Russia
Launched by EUROPEAN UNIVERSITY AT ST. PETERSBURG · May 26, 2020
Trial Information
Current as of May 12, 2025
Completed
Keywords
ClinConnect Summary
At least 1 000 individuals, 18 years old and older, are randomly sampled using random digit dialing from the population of Saint Petersburg, Russia. Random sampling is performed by a survey company on the list of mobile phone numbers with designated geography prefixes of St. Petersburg. The baseline questionnaire for computer-assisted telephone interview includes travel history, medical history, and socio-economic status of the respondents. Sampled individuals are then invited to the clinic for blood sampling, their refusal to participate is recorded. Collected blood samples are used for SA...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Individuals sampled from the population of Saint Petersburg, Russia using random digit dialling.
- • Subjects aged 18 and older of both genders.
- • Asymptomatic at the time of blood draw.
- • Written informed consent for a blood draw, SARS-COV-2 antibody test, and data collection.
- Exclusion Criteria:
- • Presence of fever or cough or respiratory distress at the time of blood test not attributable to other known chronic disease.
- • Age under 18.
- • Any health condition that may be a contraindication towards blood sampling in out-patient clinic.
- • Residence in Kolpinskiy, Kurortniy, Krasnoselsky, Kronshtadtskiy, Petrodvorcoviy, Pushkinskiy districts of St. Petersburg.
About European University At St. Petersburg
The European University at St. Petersburg is a prestigious academic institution dedicated to advancing research and education in the social sciences and humanities. As a sponsor of clinical trials, the university leverages its expertise to facilitate innovative studies aimed at enhancing public health and medical knowledge. By fostering interdisciplinary collaboration and adhering to rigorous ethical standards, the university supports the development of evidence-based interventions and contributes to the global body of clinical research. Its commitment to academic excellence and research integrity positions it as a key player in the advancement of healthcare solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Saint Petersburg, , Russian Federation
Patients applied
Trial Officials
Lubov Barabanova, MD
Principal Investigator
Clinic "Scandinavia"
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials